Updates on histiocytic disorders

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1329-1335

  Vaiselbuh, Sarah R ^a,e   Bryceson, Yenan T ^b   Allen, Carl E ^c   Whitlock, James A ^d   Abla, Oussama ^d  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e Children's Cancer Center   (United States)

Author keywords

Hemophagocytic lymphohistiocytosis; Langerhans cell histiocytosis; Rosai Dorfman disease; Targeted therapies

Indexed keywords

AFURESERTIB; B RAF KINASE; CD163 ANTIGEN; FERRITIN; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; PERFORIN; PROTEIN S 100; T6 ANTIGEN;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLONAL VARIATION; CONSCIOUSNESS DISORDER; CYTOPENIA; DEGENERATIVE DISEASE; DENDRITIC CELL; ERYTHROPHAGOCYTOSIS; FEVER; GENE FREQUENCY; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOFIBRINOGENEMIA; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY INFILTRATE; LANGERHANS CELL HISTIOCYTOSIS; LOW RISK PATIENT; MALIGNANT TRANSFORMATION; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; SINUS HISTIOCYTOSIS; SPLENOMEGALY;

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; LANGERHANS CELL HISTIOCYTOSIS; ROSAI DORFMAN DISEASE; TARGETED THERAPIES;

CONGRESSES AS TOPIC; HISTIOCYTOSIS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84899690339     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25017     Document Type: Article

References (82)

1. Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184:4557-4567.
2. Ginhoux F, Collin MP, Bogunovic M, et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. J Exp Med 2007; 204:3133-3146.
3. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8:935-947.
4. Merad M, Sathe P, Helft J, et al. The dendritic cell lineage: Ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604.
5. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994; 343:767-768.
6. Willman CL, McClain KL. An update on clonality, cytokines, and viral etiology in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:407-416.
7. Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: Biology and clinical significance. Br J Cancer Suppl 1994; 23:S29-S33.
8. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116:1919-1923.
9. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120:2700-2703.
10. Kansal R, Quintanilla-Martinez L, Datta V, et al. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer 2013; 52:99-106.
11. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012; 120:e28-e34.
12. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE 2012; 7:e33891.
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
14. Michaloglou C, Vredeveld LC, Mooi WJ, et al. BRAF(E600) in benign and malignant human tumours. Oncogene 2008; 27:877-895.
15. Tadmor T, Tiacci E, Falini B, et al. The BRAF-V600E mutation in hematological malignancies: A new player in hairy cell leukemia and Langerhans cell histiocytosis. Leuk Lymphoma 2012; 53:2339-2340.
16. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med 2007; 4:e253.
17. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001; 97:1241-1248.
18. Laman JD, Leenen PJ, Annels NE, et al. Langerhans-cell histiocytosis "insight into DC biology." Trends Immunol 2003; 24:190-196.
19. Murakami I, Morimoto A, Oka T, et al. IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy. Virchows Arch 2013; 462:219-228.
20. Allen CE, McClain KL. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med 2009; 15:483-484 ; author reply 484-485.
21. Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39:2341-2348.
22. Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 2013; 60:175-184.
23. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 2013; 121:5006-5014.
24. Minkov M, Steiner M, Potschger U, et al. Reactivations in multisystem Langerhans cell histiocytosis: Data of the international LCH registry. J Pediatr 2008; 153:700-705 705.e701-702.
25. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011; 8:426-433.
26. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK 2118 436) in patients with metastatic melanoma. J Clin Oncol 2013; 31:3205-3211.
27. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31:1767-1774.
28. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
29. Doma E, Rupp C, Varga A, et al. Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf Functions that are dependent and independent of ERK. Cancer Res 2013; 73:6926-6937.
30. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121:1495-1500.
31. Schini M, Makras P, Kanakis G, et al. Cladribine therapy in adults with advanced Langerhans cell histiocytosis. Leuk Lymphoma 2013; 54:1541-1543.
32. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41:2682-2689.
33. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother 2005; 6:2435-2441.
34. Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer 2014; 64:479-481.
35. Abraham A, Alsultan A, Jeng M, et al. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer 2013; 60:E19-E22.
36. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 2012; 63:233-246.
37. Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child 1952; 27:519-525.
38. Filipovich AH. The expanding spectrum of hemophagocytic lymphohistiocytosis. Curr Opin Allergy Clin Immunol 2011; 11:512-516.
39. Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 2011; 118:5794-5798.
40. Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: A multilayer pathogenesis of macrophage activation syndrome. J Rheumatol 2013; 40:761-767.
41. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2:735-747.
42. Pachlopnik Schmid J, Cote M, Menager MM, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010; 235:10-23.
43. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124-131.
44. Horne A, Trottestam H, Arico M, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 2008; 140:327-335.
45. Henter JI, Elinder G, Soder O, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78:2918-2922.
46. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957-1959.
47. Meeths M, Chiang SC, Wood SM, et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood 2011; 118:5783-5793.
48. Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012; 119:2754-2763.
49. Mellor-Heineke S, Villanueva J, Jordan MB, et al. Elevated Granzyme B in cytotoxic lymphocytes is a signature of immune activation in hemophagocytic lymphohistiocytosis. Front Immunol 2013; 4:72.
50. Chiang SC, Theorell J, Entesarian M, et al. Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood 2013; 121:1345-1356.
51. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118:4041-4052.
52. Henter JI, Arico M, Egeler RM, et al. HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 1997; 28:342-347.
53. Marsh RA, Kim MO, Liu C, et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant 2013; 19:1625-1631.
54. Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients. Pediatrics 2007; 120:e622-e628.
55. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013; 162:376-382.
56. Ito Y, Kawamura Y, Iwata S, et al. Demonstration of type II latency in T lymphocytes of Epstein-Barr Virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2013; 60:326-328.
57. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010; 7:415-420.
58. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013; 60:101-109.
59. Machaczka M, Vaktnas J, Chiang SC, et al. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010; 7.
60. Pachlopnik Schmid J, Ho CH, Chretien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009; 1:112-124.
61. Weitzman S, Jaffe R. Uncommon histiocytic disorders: The non-Langerhans cell histiocytoses. Pediatr Blood Cancer 2005; 45:256-264.
62. Zaba LC, Fuentes-Duculan J, Steinman RM, et al. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 2007; 117:2517-2525.
63. Shelton E, Dalton AJ. Electron microscopy of emperipolesis. J Biophys Biochem Cytol 1959; 6:513-514.
64. Foss HD, Herbst H, Araujo I, et al. Monokine expression in Langerhans' cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Pathol 1996; 179:60-65.
65. Ambati S, Chamyan G, Restrepo R, et al. Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 51:433-435.
66. Lu D, Estalilla OC, Manning JT Jr, et al. Sinus histiocytosis with massive lymphadenopathy and malignant lymphoma involving the same lymph node: A report of four cases and review of the literature. Mod Pathol 2000; 13:414-419.
67. Grabczynska SA, Toh CT, Francis N, et al. Rosai-Dorfman disease complicated by autoimmune haemolytic anaemia: Case report and review of a multisystem disease with cutaneous infiltrates. Br J Dermatol 2001; 145:323-326.
68. Kaur PP, Birbe RC, DeHoratius RJ. Rosai-Dorfman disease in a patient with systemic lupus erythematosus. J Rheumatol 2005; 32:951-953.
69. Maric I, Pittaluga S, Dale JK, et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 2005; 29:903-911.
70. Venkataraman G, McClain KL, Pittaluga S, et al. Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease. Am J Surg Pathol 2010; 34:589-594.
71. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Review of the entity. Semin Diagn Pathol 1990; 7:19-73.
72. Juskevicius R, Finley JL. Rosai-Dorfman disease of the parotid gland: Cytologic and histopathologic findings with immunohistochemical correlation. Arch Pathol Lab Med 2001; 125:1348-1350.
73. Hadjipanayis CG, Bejjani G, Wiley C, et al. Intracranial Rosai-Dorfman disease treated with microsurgical resection and stereotactic radiosurgery. Case report. J Neurosurg 2003; 98:165-168.
74. Kraeft SK, Honig M, Krishnamurthy S. Emperipolesis in the cerebrospinal fluid from a patient with Rosai-Dorfman disease. Diagn Cytopathol 2008; 36:67-68.
75. Abdollahi A, Ardalan FA, Ayati M. Extranodal Rosai-Dorfman disease of the kidney. Ann Saudi Med 2009; 29:55-57.
76. Mrad K, Charfi L, Dhouib R, et al. [Extra-nodal Rosai-Dorfman disease: A case report with thyroid involvement]. Ann Pathol 2004; 24:446-449.
77. Hida AI, Yagi S, Obase Y, et al. Rosai-Dorfman disease presenting as a solitary mediastinal mass. Pathol Int 2009; 59:265-268.
78. Miyake M, Tateishi U, Maeda T, et al. Extranodal Rosai-Dorfman disease: A solitary lesion with soft tissue reaction. Radiat Med 2005; 23:439-442.
79. Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol 2007; 143:736-740.
80. Konca C, Ozkurt ZN, Deger M, et al. Extranodal multifocal Rosai-Dorfman disease: Response to 2-chlorodeoxyadenosine treatment. Int J Hematol 2009; 89:58-62.
81. Petschner F, Walker UA, Schmitt-Graff A, et al. ["Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab]. Dtsch Med Wochenschr 2001; 126:998-1001.
82. Le Guenno G, Galicier L, Uro-Coste E, et al. Successful treatment with azathioprine of relapsing Rosai-Dorfman disease of the central nervous system. J Neurosurg 2012; 117:486-489.